Compare Target Corporation (TGT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Target Corporation trades at $153.88 (market cap $70.31B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Target Corporation is far larger — about 4.1× Zimmer Biomet Holdings Inc's market cap, and Target Corporation pays the higher dividend (3%). Which is the better fit depends on your goals — on Pluang, investors hold Target Corporation for 137 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TGT | ZBH | |
|---|---|---|
Market Cap | $70.31B | $16.95B |
Volume | 4,164,999 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $169.90 | $103.98 |
52-Week Low | $83.68 | $79.58 |
Typical Hold Time | 137 Days | 89 Days |
Enterprise Value | $83.58B | $24.02B |
Dividend Yield | 3% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target (TGT) trades at $153.77, up 1.86% today, with a bearish technical signal but strong fundamental support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.11 significantly exceeding the $2.35 estimate. Valuation ratios like a P/E of 16.05 and P/S of 0.65 appear attractive relative to historical averages. Recent news highlights strategic price cuts on 2,000 items to boost holiday sales and market share.
The outlook is cautiously optimistic, supported by solid profitability, dividend reliability, and analyst consensus pointing to upside. Key risks include competitive pressures, margin compression from pricing strategies, and broader retail sector volatility. The consensus price target of $167.18 suggests potential appreciation, but investors should weigh execution risks against growth initiatives.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
